Spero Therapeutics (SPRO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Apr, 2026Executive summary
The annual meeting will be held virtually on June 23, 2026, with voting available online, by phone, or by mail.
Stockholders will vote on five key proposals, including director elections, auditor ratification, executive compensation, an amendment to increase authorized shares, and a new stock incentive plan.
The Board recommends approval of all proposals and emphasizes the importance of stockholder participation.
Voting matters and shareholder proposals
Proposals include electing two directors, ratifying PricewaterhouseCoopers LLP as auditor, approving executive compensation, amending the certificate of incorporation to double authorized common shares, and adopting the 2026 Stock Incentive Plan.
The Board recommends voting “FOR” all proposals.
Voting can be done online, by phone, mail, or during the virtual meeting.
Shareholder proposals for the 2027 meeting must be submitted by December 28, 2026.
Board of directors and corporate governance
The Board is divided into three classes, with eight members, and a majority are independent under Nasdaq rules.
Milind Deshpande, Ph.D. and Kathleen Tregoning are nominated for re-election as Class III directors.
The Board has Audit, Compensation, Nominating and Corporate Governance, and Development Committees, all with independent members.
Corporate governance guidelines and a code of business conduct and ethics are in place.
Latest events from Spero Therapeutics
- Returned to profitability in 2025, driven by collaboration revenue and milestone payments.SPRO
Q4 202526 Mar 2026 - Q2 net loss was $17.9M as R&D spending rose; cash runway extends into late 2025.SPRO
Q2 20242 Feb 2026 - SPR720 nears pivotal data for NTM-PD, while Tebipenem HBr advances in phase III with GSK.SPRO
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Advancing late-stage anti-infective therapies with major data and regulatory milestones ahead.SPRO
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Tebipenem HBr phase III interim analysis set for Q2 2025; cash runway into Q2 2026.SPRO
Q4 202424 Dec 2025 - Lead oral carbapenem asset nears phase III completion, with major milestones expected this year.SPRO
TD Cowen 45th Annual Healthcare Conference16 Dec 2025 - Stockholders to vote on director elections, auditor, executive pay, and stock plan amendment.SPRO
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, executive pay, and stock plan share increase.SPRO
Proxy Filing2 Dec 2025 - Tebipenem HBr Phase 3 trial met efficacy early, boosting revenue and extending cash runway into 2028.SPRO
Q2 202523 Nov 2025